Rituximab versus mitoxantrone: comparing effectiveness and safety in advanced relapsing multiple sclerosis.

ABSTRACT:

Background

Rituximab (RTX), a CD20 depleting agent, is a frequently used off-label treatment for multiple sclerosis (MS), while mitoxantrone (MTX) is approved, albeit rarely used for active relapsing MS (RMS). However, observational data comparing RTX and MTX effectiveness and safety are scarce.

Objective

We aimed to compare effectiveness and safety of MTX and RTX in patients with active RMS.

Methods

From combined retrospective clinical data of three MS centers, we selected patients who had received at least one infusion of RTX or MTX and had at least a 6-month clinical follow-up available. Treatment groups were compared by propensity score (PS)-adjusted regression and inverse PS-weighted generalized estimated equation models regarding disability progression, relapse

SUBMITTER: Zrzavy T 

PROVIDER: S-EPMC8323410 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature